Molecularly targeted agents as radiosensitizers in cancer therapy-focus on prostate cancer

Sara Alcorn, Amanda J. Walker, Nishant Gandhi, Amol Narang, Aaron T. Wild, Russell Hales, Joseph M. Herman, Danny Y Song, Theodore DeWeese, Emmanuel Antonarakis, Phuoc T Tran

Research output: Contribution to journalArticle

Abstract

As our understanding of the molecular pathways driving tumorigenesis improves and more druggable targets are identified, we have witnessed a concomitant increase in the development and production of novel molecularly targeted agents. Radiotherapy is commonly used in the treatment of various malignancies with a prominent role in the care of prostate cancer patients, and efforts to improve the therapeutic ratio of radiation by technologic and pharmacologic means have led to important advances in cancer care. One promising approach is to combine molecularly targeted systemic agents with radiotherapy to improve tumor response rates and likelihood of durable control. This review first explores the limitations of preclinical studies as well as barriers to successful implementation of clinical trials with radiosensitizers. Special considerations related to and recommendations for the design of preclinical studies and clinical trials involving molecularly targeted agents combined with radiotherapy are provided. We then apply these concepts by reviewing a representative set of targeted therapies that show promise as radiosensitizers in the treatment of prostate cancer.

Original languageEnglish (US)
Pages (from-to)14800-14832
Number of pages33
JournalInternational Journal of Molecular Sciences
Volume14
Issue number7
DOIs
StatePublished - Jul 2013

Fingerprint

Radiotherapy
radiation therapy
therapy
Prostatic Neoplasms
cancer
Neoplasms
reviewing
Clinical Trials
recommendations
Tumors
Therapeutics
tumors
Radiation
Carcinogenesis
radiation

Keywords

  • HSP90 inhibitors
  • Molecularly targeted agents
  • Prostate cancer
  • Radiosensitizer
  • Radiotherapy

ASJC Scopus subject areas

  • Computer Science Applications
  • Molecular Biology
  • Catalysis
  • Inorganic Chemistry
  • Spectroscopy
  • Organic Chemistry
  • Physical and Theoretical Chemistry

Cite this

Molecularly targeted agents as radiosensitizers in cancer therapy-focus on prostate cancer. / Alcorn, Sara; Walker, Amanda J.; Gandhi, Nishant; Narang, Amol; Wild, Aaron T.; Hales, Russell; Herman, Joseph M.; Song, Danny Y; DeWeese, Theodore; Antonarakis, Emmanuel; Tran, Phuoc T.

In: International Journal of Molecular Sciences, Vol. 14, No. 7, 07.2013, p. 14800-14832.

Research output: Contribution to journalArticle

@article{1c66af56cf084696adfca03b330bb335,
title = "Molecularly targeted agents as radiosensitizers in cancer therapy-focus on prostate cancer",
abstract = "As our understanding of the molecular pathways driving tumorigenesis improves and more druggable targets are identified, we have witnessed a concomitant increase in the development and production of novel molecularly targeted agents. Radiotherapy is commonly used in the treatment of various malignancies with a prominent role in the care of prostate cancer patients, and efforts to improve the therapeutic ratio of radiation by technologic and pharmacologic means have led to important advances in cancer care. One promising approach is to combine molecularly targeted systemic agents with radiotherapy to improve tumor response rates and likelihood of durable control. This review first explores the limitations of preclinical studies as well as barriers to successful implementation of clinical trials with radiosensitizers. Special considerations related to and recommendations for the design of preclinical studies and clinical trials involving molecularly targeted agents combined with radiotherapy are provided. We then apply these concepts by reviewing a representative set of targeted therapies that show promise as radiosensitizers in the treatment of prostate cancer.",
keywords = "HSP90 inhibitors, Molecularly targeted agents, Prostate cancer, Radiosensitizer, Radiotherapy",
author = "Sara Alcorn and Walker, {Amanda J.} and Nishant Gandhi and Amol Narang and Wild, {Aaron T.} and Russell Hales and Herman, {Joseph M.} and Song, {Danny Y} and Theodore DeWeese and Emmanuel Antonarakis and Tran, {Phuoc T}",
year = "2013",
month = "7",
doi = "10.3390/ijms140714800",
language = "English (US)",
volume = "14",
pages = "14800--14832",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "7",

}

TY - JOUR

T1 - Molecularly targeted agents as radiosensitizers in cancer therapy-focus on prostate cancer

AU - Alcorn, Sara

AU - Walker, Amanda J.

AU - Gandhi, Nishant

AU - Narang, Amol

AU - Wild, Aaron T.

AU - Hales, Russell

AU - Herman, Joseph M.

AU - Song, Danny Y

AU - DeWeese, Theodore

AU - Antonarakis, Emmanuel

AU - Tran, Phuoc T

PY - 2013/7

Y1 - 2013/7

N2 - As our understanding of the molecular pathways driving tumorigenesis improves and more druggable targets are identified, we have witnessed a concomitant increase in the development and production of novel molecularly targeted agents. Radiotherapy is commonly used in the treatment of various malignancies with a prominent role in the care of prostate cancer patients, and efforts to improve the therapeutic ratio of radiation by technologic and pharmacologic means have led to important advances in cancer care. One promising approach is to combine molecularly targeted systemic agents with radiotherapy to improve tumor response rates and likelihood of durable control. This review first explores the limitations of preclinical studies as well as barriers to successful implementation of clinical trials with radiosensitizers. Special considerations related to and recommendations for the design of preclinical studies and clinical trials involving molecularly targeted agents combined with radiotherapy are provided. We then apply these concepts by reviewing a representative set of targeted therapies that show promise as radiosensitizers in the treatment of prostate cancer.

AB - As our understanding of the molecular pathways driving tumorigenesis improves and more druggable targets are identified, we have witnessed a concomitant increase in the development and production of novel molecularly targeted agents. Radiotherapy is commonly used in the treatment of various malignancies with a prominent role in the care of prostate cancer patients, and efforts to improve the therapeutic ratio of radiation by technologic and pharmacologic means have led to important advances in cancer care. One promising approach is to combine molecularly targeted systemic agents with radiotherapy to improve tumor response rates and likelihood of durable control. This review first explores the limitations of preclinical studies as well as barriers to successful implementation of clinical trials with radiosensitizers. Special considerations related to and recommendations for the design of preclinical studies and clinical trials involving molecularly targeted agents combined with radiotherapy are provided. We then apply these concepts by reviewing a representative set of targeted therapies that show promise as radiosensitizers in the treatment of prostate cancer.

KW - HSP90 inhibitors

KW - Molecularly targeted agents

KW - Prostate cancer

KW - Radiosensitizer

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84880751541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880751541&partnerID=8YFLogxK

U2 - 10.3390/ijms140714800

DO - 10.3390/ijms140714800

M3 - Article

VL - 14

SP - 14800

EP - 14832

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 7

ER -